|  |
| --- |
| **Supporting Table 1. Five-year relative survival of malignant cancer by International Classification of Childhood Cancers group in individuals <20 years of age, United States, cases diagnosed during 2001–2015** |
|   | 2001–2015 |   | 2001–2007 |   | 2008–2015 |
| **ICCC group** | Count | Relative survival (95% CI) |   | Count | Relative survival (95% CI) |   | Count | Relative survival (95% CI) |
| I Leukemias, myeloproliferative & myelodysplastic diseases | 48,629 | 83.3 (83.0–83.7) |   | 23,512 | 81.2 (80.7–81.7) |   | 25,117 | **85.7 (85.2–86.2)** |
|  I(a) Lymphoid leukemias | 35,131 | 88.2 (87.8–88.5) |   | 16,959 | 86.6 (86.1–87.2) |   | 18,172 | **89.8 (89.3–90.3)** |
|  I(b) Acute myeloid leukemias | 8,060 | 63.8 (62.7–64.9) |   | 4,017 | 60.0 (58.5–61.5) |   | 4,043 | **68.2 (66.6–69.7)** |
|  I(c) Chronic myeloproliferative diseases | 2,573 | 92.1 (90.9–93.1) |   | 1,207 | 89.2 (87.3–90.8) |   | 1,366 | **94.9 (93.4–96.1)** |
|  I(d) Myelodysplastic syndrome and other myeloproliferative | 1,483 | 70.3 (67.8–72.6) |   | 725 | 69.9 (66.4–73.1) |   | 758 | 70.9 (67.2–74.2) |
|  I(e) Unspecified and other specified leukemias | 1,382 | 72.2 (69.7–74.6) |   | 604 | 66.4 (62.5–70.0) |   | 778 | **77.5 (74.1–80.6)** |
| II Lymphomas and reticuloendothelial neoplasms | 27,967 | 91.9 (91.5–92.2) |   | 13,067 | 90.0 (89.4–90.5) |   | 14,900 | **93.7 (93.3–94.1)** |
|  II(a) Hodgkin lymphomas | 13,242 | 96.0 (95.6–96.3) |   | 6,603 | 95.3 (94.8–95.8) |   | 6,639 | **96.7 (96.2–97.2)** |
|  II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma) | 9,276 | 85.8 (85.0–86.5) |   | 4,442 | 82.9 (81.8–84.0) |   | 4,834 | **88.7 (87.7–89.6)** |
|  II(c) Burkitt lymphoma | 2,569 | 89.9 (88.6–91.0) |   | 1,306 | 88.2 (86.3–89.9) |   | 1,263 | 91.5 (89.7–93.0) |
|  II(d) Miscellaneous lymphoreticular neoplasms | 2,529 | 95.5 (94.6–96.3) |   | 551 | 88.7 (85.7–91.1) |   | 1,978 | **97.7 (96.9–98.3)** |
|  II(e) Unspecified lymphomas | 351 | 88.7 (84.7–91.6) |   | 165 | 84.4 (77.9–89.1) |   | 186 | 92.3 (86.7–95.6) |
| III CNS and misc intracranial and intraspinal neoplasms | 32,879 | 74.9 (74.4–75.4) |   | 15,920 | 73.7 (73.0–74.4) |   | 16,959 | **76.4 (75.7–77.0)** |
|  III(a) Ependymomas and choroid plexus tumor | 2,807 | 77.7 (76.0–79.3) |   | 1,407 | 74.9 (72.6–77.1) |   | 1,400 | **81.3 (78.8–83.6)** |
|  III(b) Astrocytomas | 16,895 | 83.8 (83.3–84.4) |   | 8,022 | 83.9 (83.1–84.7) |   | 8,873 | 83.9 (83.1–84.7) |
|  III(c) Intracranial and intraspinal embryonal tumors | 6,480 | 63.2 (62.0–64.4) |   | 3,270 | 61.6 (59.9–63.2) |   | 3,210 | **65.1 (63.3–66.9)** |
|  III(d) Other gliomas | 5,610 | 61.9 (60.6–63.2) |   | 2,680 | 59.0 (57.1–60.9) |   | 2,930 | **64.9 (63.1–66.7)** |
|  III(e) Other specified intracranial/intraspinal neoplasms | 680 | 71.1 (67.3–74.5) |   | 344 | 70.5 (65.4–75.0) |   | 336 | 72.2 (66.4–77.1) |
|  III(f) Unspecified intracranial and intraspinal neoplasms | 407 | 58.3 (53.3–63.0) |   | 197 | 55.5 (48.2–62.1) |   | 210 | 61.8 (54.7–68.1) |
| IV Neuroblastoma and other peripheral nervous cell tumors | 9,030 | 78.8 (77.9–79.7) |   | 4,448 | 76.6 (75.3–77.8) |   | 4,582 | 81.2 (79.8–82.5) |
|  IV(a) Neuroblastoma and ganglioneuroblastoma | 8,779 | 78.6 (77.6–79.5) |   | 4,339 | 76.4 (75.1–77.7) |   | 4,440 | 81.0 (79.6–82.3) |
|  IV(b) Other peripheral nervous cell tumors | 251 | 86.3 (81.1–90.2) |   | 109 | 84.6 (76.3–90.2) |   | 142 | 87.1 (79.0–92.2) |
| V Retinoblastoma | 3,406 | 97.2 (96.5–97.7) |   | 1,644 | 97.2 (96.2–98.0) |   | 1,762 | 97.1 (96.0–97.9) |
| VI Renal tumors | 7,277 | 89.9 (89.1–90.6) |   | 3,489 | 88.1 (87.0–89.2) |   | 3,788 | **91.6 (90.6–92.5)** |
|  VI(a) Nephroblastoma and other nonepithelial renal tumors | 6,625 | 91.1 (90.3–91.8) |   | 3,185 | 89.3 (88.1–90.3) |   | 3,440 | **92.9 (91.9–93.8)** |
|  VI(b) Renal carcinomas | 625 | 77.3 (73.6–80.5) |   | 289 | 76.0 (70.6–80.5) |   | 336 | 78.1 (72.7–82.6) |
| **Supporting Table 1. (continued)**  VI(c) Unspecified malignant renal tumors | 27 | 83.9 (61.5–93.9) |   | – |   |   | – |   |
| VII Hepatic tumors | 2,395 | 68.2 (66.2–70.1) |   | 1,093 | 64.2 (61.2–66.9) |   | 1,302 | **72.2 (69.5–74.7)** |
|  VII(a) Hepatoblastoma | 1,749 | 76.7 (74.6–78.7) |   | 779 | 74.1 (70.8–77.0) |   | 970 | 79.2 (76.3–81.8) |
|  VII(b) Hepatic carcinomas | 625 | 44.6 (40.5–48.7) |   | 305 | 38.5 (33.0–43.9) |   | 320 | **51.9 (45.7–57.8)** |
|  VII(c) Unspecified malignant hepatic tumors | 21 | 62.1 (38.2–79.0) |   | – |   |   | – |   |
| VIII Malignant bone tumors | 9,213 | 70.7 (69.6–71.6) |   | 4,631 | 70.1 (68.7–71.4) |   | 4,582 | 71.3 (69.8–72.8) |
|  VIII(a) Osteosarcomas | 5,177 | 67.4 (66.0–68.8) |   | 2,610 | 67.6 (65.8–69.4) |   | 2,567 | 67.2 (65.0–69.3) |
|  VIII(b) Chondrosarcomas | 360 | 94.4 (91.2–96.5) |   | 181 | 93.1 (88.2–96.0) |   | 179 | 96.3 (91.4–98.4) |
|  VIII(c) Ewing tumor and related sarcomas of bone | 3,030 | 70.2 (68.4–71.9) |   | 1,520 | 68.6 (66.2–70.9) |   | 1,510 | 72.0 (69.2–74.6) |
|  VIII(d) Other specified malignant bone tumors | 472 | 88.4 (84.8–91.1) |   | 231 | 86.0 (80.7–89.9) |   | 241 | 90.9 (85.6–94.4) |
|  VIII(e) Unspecified malignant bone tumors | 174 | 79.2 (72.0–84.8) |   | 89 | 78.9 (68.8–86.0) |   | 85 | 80.0 (68.5–87.7) |
| IX Soft tissue and other extraosseous sarcomas | 12,496 | 74.1 (73.2–74.9) |   | 6,186 | 73.6 (72.4–74.6) |   | 6,310 | 74.6 (73.4–75.8) |
|  IX(a) Rhabdomyosarcomas | 4,913 | 68.0 (66.6–69.3) |   | 2,459 | 68.1 (66.2–69.9) |   | 2,454 | 67.6 (65.5–69.6) |
|  IX(b) Fibrosarcomas, peripheral nerve & other fibrous | 1,316 | 79.3 (76.9–81.5) |   | 671 | 77.8 (74.4–80.8) |   | 645 | 81.4 (77.8–84.5) |
|  IX(c) Kaposi sarcoma | 52 | 82.7 (69.1–90.7) |   | 21 | 81.2 (56.9–92.6) |   | 31 | 83.9 (65.3–93.1) |
|  IX(d) Other specified soft tissue sarcomas | 4,903 | 78.6 (77.4–79.8) |   | 2,434 | 78.3 (76.6–79.9) |   | 2,469 | 78.9 (77.1–80.7) |
|  IX(e) Unspecified soft tissue sarcomas | 1,312 | 74.6 (72.0–76.9) |   | 601 | 71.7 (67.9–75.2) |   | 711 | 77.3 (73.8–80.4) |
| X Germ cell & trophoblastic tumors & neoplasms of gonads | 11,839 | 92.4 (91.9–92.9) |   | 5,698 | 92.0 (91.3–92.7) |   | 6,141 | 92.9 (92.1–93.6) |
|  X(a) Intracranial & intraspinal germ cell tumors | 1,760 | 87.8 (86.1–89.3) |   | 828 | 85.8 (83.2–88.0) |   | 932 | 89.9 (87.5–91.8) |
|  X(b) Extracranial & extragonadal germ cell tumors | 1,553 | 84.5 (82.5–86.3) |   | 775 | 84.9 (82.2–87.3) |   | 778 | 84.2 (81.2–86.7) |
|  X(c) Malignant gonadal germ cell tumors | 7,727 | 96.4 (96.0–96.9) |   | 3,716 | 96.3 (95.6–96.9) |   | 4,011 | 96.6 (95.9–97.2) |
|  X(d) Gonadal carcinomas | 456 | 78.1 (73.8–81.8) |   | 209 | 79.1 (72.9–84.0) |   | 247 | 76.9 (70.2–82.2) |
|  X(e) Other and unspecified malignant gonadal tumors | 343 | 80.0 (75.0–84.1) |   | 170 | 77.2 (70.1–82.9) |   | 173 | 83.0 (75.1–88.6) |
| XI Other malignant epithelial neoplasms and melanomas | 19,114 | 93.3 (92.9–93.7) |   | 9,025 | 93.2 (92.6–93.7) |   | 10,089 | 93.3 (92.8–93.9) |
|  XI(a) Adrenocortical carcinomas | 228 | 60.8 (53.8–67.0) |   | 103 | 70.0 (60.1–77.9) |   | 125 | 50.9 (40.5–60.4) |
|  XI(b) Thyroid carcinomas | 8,192 | 99.4 (99.1–99.6) |   | 3,352 | 99.3 (98.9–99.6) |   | 4,840 | 99.4 (99.0–99.6) |
|  XI(c) Nasopharyngeal carcinomas | 610 | 86.2 (83.0–88.8) |   | 303 | 84.2 (79.5–87.9) |   | 307 | 88.4 (83.4–91.9) |
|  XI(d) Malignant melanomas | 5,395 | 95.6 (95.0–96.1) |   | 3,119 | 96.1 (95.3–96.7) |   | 2,276 | 94.8 (93.6–95.7) |
|  XI(e) Skin carcinomas | 86 | 96.6 (89.4–98.9) |   | 44 | 95.5 (83.0–98.9) |   | 42 | 97.5 (82.2–99.7) |
|  XI(f) Other and unspecified carcinomas | 4,603 | 82.3 (81.1–83.4) |   | 2,104 | 81.4 (79.7–83.0) |   | 2,499 | 82.9 (81.2–84.5) |
| XII Other and unspecified malignant neoplasms | 798 | 80.8 (77.8–83.5) |   | 433 | 80.4 (76.3–83.8) |   | 365 | 81.7 (77.0–85.5) |
|  XII(a) Other specified malignant tumors | 411 | 80.9 (76.6–84.5) |   | 211 | 76.0 (69.6–81.2) |   | 200 | 87.0 (81.0–91.2) |
| **Supporting Table 1. (continued)** |  |  |  |  |  |  |  |  |
|  XII(b) Other unspecified malignant tumors | 387 | 80.7 (76.3–84.4) |   | 222 | 84.4 (78.9–88.6) |   | 165 | 75.2 (67.2–81.5) |
| Not classified by ICCC or in situ | 269 | 64.8 (58.6–70.3) |   | 129 | 63.0 (54.0–70.7) |   | 140 | 66.8 (57.9–74.3) |
|   |   |   |   |   |   |   |   |   |
| Source: CDC’s National Program of Cancer Registries. |   |   |   |   |   |   |   |   |
| Abbreviations: CI=confidence interval, ICCC=International Classification of Childhood Cancers. |   |   |   |   |   |   |
| Bold indicates nonoverlapping 95% CIs when comparing 2001–2007 to 2008–2015. |   |   |   |   |   |   |   |
| – indicates suppressed cell due to case count <16. |   |   |   |   |   |   |   |   |